Legend Biotech USA Inc. Signs Lease for New Global Headquarters in Bridgewater, New Jersey

Reuters
14 May
Legend Biotech USA Inc. Signs Lease for New Global Headquarters in Bridgewater, New Jersey

Legend Biotech Corporation's subsidiary, Legend Biotech USA Inc., has signed an Office Lease Agreement for its new global corporate headquarters in Bridgewater, New Jersey. The lease, effective from June 1, 2025, to April 2036, involves renting 57,325 square feet of space at 77 Corporate Drive. The base annual rent will range from approximately $1.9 million to $2.3 million, with a rent abatement for the first eight and last two months of the lease. Legend Biotech also retains options to extend the lease and rights to lease additional space in the building.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-003155), on May 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10